Glioma is one of the most common malignant brain tumors and exhibits low resection rate and 20 high recurrence risk. Although a large number of glioma studies powered by high-throughput 21 sequencing technologies have led to massive multi-omics datasets, there lacks of 22 comprehensive integration of glioma datasets for uncovering candidate biomarker genes. In this 23 study, we collected a large-scale assemble of multi-omics multi-cohort datasets from worldwide 24 public resources, involving a total of 16,939 samples across 19 independent studies. Through 25 comprehensive multi-omics molecular profiling across different datasets, we revealed that 26 PRKCG (Protein Kinase C Gamma), a brain-specific gene detectable in cerebrospinal fluid, is 27 closely associated with glioma. Specifically, it presents lower expression and higher 28 methylation in glioma samples compared with normal samples. PRKCG 29 expression/methylation change from high to low is indicative of glioma progression from low-30 grade to high-grade and high RNA expression is suggestive of good survival. Importantly, 31 PRKCG in combination with MGMT is effective to predict survival outcomes after TMZ 32 chemotherapy in a more precise manner. Collectively, PRKCG bears the great potential for 33 glioma diagnosis, prognosis and therapy, and PRKCG-like genes may represent a set of 34 important genes associated with different molecular mechanisms in glioma tumorigenesis. 35
Introduction 6 http://www.cgga.org.cn) (41, 42) . Particularly, discovery datasets were derived from TCGA, 109
GTEx and large cohort studies in GEO (GSE83710, GSE16011 and GSE36278 for protein, 110 expression and methylation, respectively). As a result, a total of five discovery datasets and 111 fourteen validation datasets were obtained. For convenience, each dataset collected in this study 112 is assigned a unique accession number with the format:
[TCGA/GTEx/GEO/CGGA/Ivy GAP]-[E/V/P/M], where D/V in the first bracket represents the 114 dataset for discovery or validation, i in the second bracket indicates the dataset number, the 115 third bracket shows the data source (as mentioned above), and the last bracket indicates the data 116 type, namely, E for RNA expression, V for CNV, P for protein expression and M for DNA 117 methylation, respectively. The detailed information about all collected datasets was tabulated 118
in Table 1 . 119
Identification of brain-specific genes 120
To identify brain-specific genes, we used the RNA-Seq dataset from GTEx (2016-01-15; v7) 121 (39), which contains 11,688 samples across 53 tissue sites of 714 donors. Considering that 122 several tissues have multiple different sites, gene expression levels were averaged over sites 123 that are from the same tissue. To reduce background noise, genes with maximal expression 124 levels smaller than 10 TPM (Transcripts Per Million) were removed. Finally, we obtained a 125 total of 15,176 gene expression profiles across 30 tissues (S1 Table) . 126
Based on the expression levels across 30 tissues, we calculated the tissue specificity index τ 127 (43) for each gene to identify tissue-specific genes. τ is valued between 0 and 1, where 0 128 represents housekeeping genes that are consistently expressed in different tissues, and 1 129 indicates tissue-specific genes that are exclusively expressed in only one tissue (43) . In this 130 study, brain-specific genes were defined as those genes that are maximally expressed in the 131 brain with τ>0.9. As a consequence, a list of the top 100 brain-specific genes ranked by the τ 132 index were obtained for further analysis (S2 Table) . 133
Sample classification

134
To comprehensively study the potential of PRKCG in glioma diagnosis, we compared the 135 molecular profiles between normal and glioma samples, between LGG and GBM samples, 136 between primary GBM (pGBM) and recurrent GBM (rGBM) samples, and between glioma 137 samples with different anatomic features. We collected 122 GBM samples from the Ivy GAP 138 database (40) and grouped them according to their anatomic regions, namely, leading edge (LE, 139 the ratio of tumor/normal cells is about 1-3/100), infiltrating tumor (IT, the ratio of 140 tumor/normal cells is about 10-20/100), cellular tumor (CT, the ratio of tumor/normal cells is 141 about 100/1 to 500/1), pseudo-palisading cells around necrosis (PAN, the narrow boundary of 142 cells along the dead tissue), and microvascular proliferation (MVP, two or more blood vessels 143 sharing a common vessel wall of endothelial). 144
We investigated the prognostic role of PRKCG by dividing samples into subgroups based on 145 PRKCG's expression level within all glioma samples and also within LGG and GBM samples, 146 respectively. When exploring the predictive role of PRKCG, we obtained DNA methylation 147 status (methylated and unmethylated) directly from the original study (35) , which was defined 148 based on the beta value cutoff 0.3. 149
Identification of PRKCG-like genes 150
Genes that satisfy the following criteria were regarded as PRKCG-like genes: (1) Higher 151 methylation level of at least one CpG site (promoter region) in glioma samples than normal 152 samples; (2) Higher DNA methylation level in LGG samples than GBM samples; (3) Higher 153 expression level in LGG samples than GBM samples; and (4) Lower expression level in glioma 154 samples than normal samples. As a result, we obtained a total of 542 PRKCG-like genes, which 155 were further divided into two groups according to their correlations between gene expression 156 and methylation, namely, 114 genes with negative correlation and 297 genes with positive 157 correlation. 158
Statistical analysis
159 All statistical analyses were performed using R version 3.3.2. The Wilcoxon test was used for 160 the analysis of the difference in gene expression/methylation between tumor and normal 161 samples, and between different glioma subtypes. The statistical significance levels were coded 162 by ns (not significant) p > 0.05, * p < 0.05, ** p < 0.01 and *** p < 0.001. We performed the 163 survival analysis using the Kaplan-Meier method and estimated the statistical difference using 164 the log-rank test. 165
Data availability statement
166
All datasets integrated in this study were obtained from multiple public database resources (see 167 details in Table 1 ), which are freely available at ftp://download.big.ac.cn/glioma_data/. 168
Results and Discussion
169
PRKCG is a brain-specific gene and detectable in cerebrospinal fluid 170
Tissue-specific genes are believed to be crucial for identifying potential biomarkers with high 171 specificity (44-48). To identify candidate genes with brain specificity, we integrated expression 172 data from GTEx (D1-GTEx-E) (39), explored all genes' expression profiles and their tissue 173 specificity, and identified a list of top 100 brain-specific genes (S2 Table) . To achieve the 174 detectability in the periphery, we assembled a total of 1,126 CSF-detectable proteins from GEO 175 (D2-GSE83710-P) (49), due to the critical significance of CSF as a feasible means to detect 176 genes expressed in human CNS (50, 51). After integrating brain-specific genes with CSF 177 proteins, we revealed that there are five brain-specific proteins that can be detected in CSF ( is highly expressed in glioma and may promote cell motility of brain tumor cells (52, 53). In 182 addition, the fusion event between BCAN and NTRK1 (BCAN-NTRK1) is a potential glioma 183 driver and therapeutic target (54). OPCML encodes a member of the IgLON subfamily in the 184 immunoglobulin proteins and is down-regulated in gliomas and other brain tumors (55, 56). 185 GFAP, encoding one of the major intermediate filament proteins of mature astrocytes (57), can 186 be used to assess the differentiation state of astrocytoma (58). CAMK2A is a calcium 187 calmodulin-dependent protein kinase and reduced expression of CAMK2A is associated with 188 better survival in GBM (59, 60). 189
Remarkably, PRKCG (Protein Kinase C Gamma), a member of protein kinase C (PKC) family 190 located in 19q, exhibits higher fluorescence intensity than the other four genes (Fig 1 and S1 191 Fig) . The expression profile of PRKCG across multiple brain developmental stages reveals that 192 its expression is extremely lower in the prenatal stages, but dramatically increases in the infancy 193 stages and is stabilized in the latter stages according to GenTree (S3 Fig) (61) . Previous studies 194 have documented that unlike other PKC family members that are expressed in many tissues 195 aside from brain, PRKCG is brain-specifically expressed (62) and that mutations in PRKCG are 196 associated with spinocerebellar ataxia (63, 64). Additionally, it has been reported that PKC 197 signaling pathways contribute to the aggressive behavior of glioma cells (65) and atypical PKC 198 isozymes are fundamental regulators of tumorigenesis (66). To our knowledge, several genes 199 in 19q are closely associated with glioma (e.g., TTYH1, UBE2S (67, 68)). However, the 200 potential role of PRKCG in glioma remains unknown, and therefore, comprehensive molecular 201 characterization of PRKCG across multi-omics glioma datasets is highly desirable. 202
PRKCG is significantly differentially expressed among normal, LGG and GBM samples 203
We first investigated the expression pattern of PRKCG among normal, LGG and GBM samples 204 by using multiple discovery and validation datasets. We found that PRKCG expression is 205 significantly reduced in gliomas by contrast to normal samples (Fig 2A- 
Wilcoxon test). Furthermore, we discovered that PRKCG shows significantly different 207 expression profiles among different anatomic regions ( Fig presumably suggest that PRKCG is closely associated with glioma and its reduced expression 217 is coupled with glioma progression (Fig 2) , highlighting its possible potential for glioma 218 diagnosis. 219 PRKCG expression is highly sensitive to survival 220 PRKCG expression change from high to low is indicative of progression from normal to glioma 221 and from LGG to GBM (Fig 2) , implying that PRKCG expression is significantly associated 222 with glioma progression. Importantly, we observed that PRKCG expression is significantly 223 associated with survival rate, which is testified by multiple independent datasets (Fig 3) . 224
Specifically, higher expression of PRKCG is indicative of longer overall survival in all glioma 225 samples ( Fig 3A-B ; p-value < 0.01, log-rank test). When separating LGG samples from GBM 226 samples, it is consistently observed that higher expression, albeit not statistically significant in 227 all examined datasets, tends to have longer overall survival in both LGG and GBM samples 228 ( Fig 3C-F) . Obviously, PRKCG expression has the potential capability to differentiate samples 229 with diverse survival states, which would be of critical significance for accurate glioma 230 subtyping, better therapeutic decisions and precision healthcare. 231
PRKCG is significantly differentially methylated among normal, LGG and GBM samples 232
Since PRKCG harbors two CpG sites (namely, cg26626089 and cg04518808) that are located 233 in the promoter region and covered in both HumanMethylation27 (27K) and 234 HumanMethylation450 (450K) BeadChip datasets, we then systematically investigated DNA 235 methylation profiles of these two sites among normal, LGG and GBM samples. Apparently, the 236 two sites show hypermethylation in GBM patients compared with normal samples (Fig 4) , 237 which is more significant for cg26626089 ( Fig It is known that MGMT encodes a DNA-repair protein and hypermethylation of MGMT is 257 associated with diminished DNA-repair activity, accordingly allowing the alkylating drug 258 temozolomide (TMZ) to have greater effect in GBM treatment (71, 72). In our study, we 259 obtained consistent results that patients with methylated MGMT are more sensitive to TMZ 260 treatment than those with unmethylated MGMT (Fig 5A; 
Considering that a single molecular biomarker might be lack of sufficient prediction power and 262 thus fail to determine the clinical therapeutic efficacy due to tumor heterogeneity (73), we 263 sought to examine the predictive potential of PRKCG for TMZ using 228 GBM samples with 264 matched DNA methylation and clinical data. We discovered that among the two CpG sites of 265 PRKCG (cg26626089 and cg04518808), cg26626089 is able to classify patients into two 266 groups with distinct survival advantages, as patients with methylated cg26626089 have 267 significantly longer survival than those with unmethylated cg26626089 ( Fig 5B and S7A Fig) . 
Multi-omics molecular profiles of PRKCG 280
Based on multi-omics profiles of PRKCG, we explored the relationship between PRKCG and 281 classical molecular features/glioma grades. First, PRKCG is located on the chromosome 282 19q13.42, unifying previous findings that 1p/19q codel is closely associated with glioma. 283
Consistently, PRKCG CNV is closely associated with 19q status ( Fig 6A and S8 Fig) . Second, 284
PRKCG methylation (cg26626089) is associated with IDH status, agreeing well with the 285 finding that IDH-mut is an initiating event that remodels the glioma methylome, resulting in 286 extensive DNA hypermethylation (12, 74) and thus most likely indicating that PRKCG 287 methylation is a passenger of IDH-mut status. As LGG samples are always associated with 288 IDH-mut and GBM samples are associated with IDH-WT, it is not difficult to understand why 289 the methylation level of PRKCG is significantly lower in GBM than in LGG ( Fig 4E-H) . At the 290 same time, such higher expression level and higher methylation level lead to the suspicion 291 whether PRKCG expression in glioma is positively regulated by its DNA methylation or is 292 attributable to its CNV. 293
As expected, when considering CNV loss and gain separately, PRKCG CNV is positively 294 correlated with its expression, as observed in the CNV loss and gain groups, respectively ( Fig  295   6B and 6C; p-value < 0.01, Spearman correlation = 0.26/0.32). However, such positive 296 correlation is absent when ignoring the difference of CNV status ( Fig 6D) . According to the 297 dosage effect theory (75), the CNV loss group should not express more PRKCG than the CNV 298 gain group. This implies that there is probably another factor rather than CNV to dominantly 299 regulate PRKCG expression in glioma. Although it contradicts the commonly accepted negative 300 association between gene expression and promoter CpG methylation, a large-scale pan-cancer 301 analysis has also revealed a positive correlation between promoter CpG methylation and gene 302 expression (76). Consistently, we did observe significant positive correlations between PRKCG 303 expression and CpG methylation within the promoter region ( Fig 6E and 6F ). This positive 304 regulation of CpG methylation is quite strong, which significantly improves PRKCG expression 305 in LGG samples; even these samples exhibit obvious CNV loss ( Fig 6A) . Thus, it is presumably 306 suggested that PRKCG is most likely regulated in different ways by DNA methylation, which 307 negatively regulates PRKCG expression from normal to tumor but positively regulates the 308 expression within tumor. However, gene expression regulation is a more complicated process 309 involving multiple factors aside from DNA methylation and CNV and more efforts on 310 comprehensive and in-depth molecular characterization of glioma are highly needed to 311 elucidate glioma pathogenesis. 312
PRKCG-like genes may present heterogeneous roles in glioma tumorigenesis
313
To better understand the regulation pattern of PRKCG, we further identified a total of 542 314 PRKCG-like genes that possess expression and DNA methylation patterns similar with PRKCG 315 (see Materials and Methods) and investigated whether these genes present heterogeneous roles 316 in glioma tumorigenesis ( Fig 7A-B and S3 Table) . Noticeably, some of these PRKCG-like 317 genes have already been reported to be closely related with glioma (77-81). For instance, 318 AKAP6 (A-kinase anchoring protein 6) polymorphisms are associated with glioma 319 susceptibility and prognosis (80); Phosphorylated SATB1 (SATB homeobox 1) contributes to 320 the invasive and proliferative of GBM cells and is associated with glioma prognosis (77); 321
Higher expression of CDK17 (cyclin dependent kinase 17) is indicative of longer overall 322 survival (78); PTPRM (protein tyrosine phosphatase receptor type M) expression is 323 significantly reduced in GBM by contrast to LGG and higher expression is indicative of longer 324 overall survival (79); and CHD5 (chromodomain helicase DNA binding protein 5) might act as 325 a tumor suppressor and its lower expression is associated with poor prognosis in glioma (81). 326 Among these PRKCG-like genes, we revealed that 114 genes show negative correlations 327 between methylation level and expression level, whereas 297 genes present positive 328 correlations (S3 Table) . We further performed gene set enrichment analysis for these two 329 groups' genes. We found that the negatively-correlated genes are primarily enriched in the 330 MAPK and cGMP-PKG signaling pathways, which are essential for tumor cell proliferation 331 and differentiation (82, 83). On the contrary, the positively-correlated genes are significantly 332 involved in pathways relevant to cancer, inflammation and nerve synapse ( Fig 7C) . Thus, 333
PRKCG-like genes that exhibit the positive correlation between DNA methylation and 334 expression, presumably present heterogeneous roles in glioma tumorigenesis with complex 335 molecular mechanisms that need further extensive explorations both bioinformatically and 336 experimentally. 337
Conclusion 338
The rapid advancement of sequencing technologies enables large amounts of glioma data 339 generated from different projects and studies throughout the world. Therefore, it has become 340 crucially significant on how to make full use of these valuable data for computational 341 identification and characterization of glioma candidate biomarkers. In this study, we, for the 342 first time, assembled the most comprehensive collection of public glioma datasets with multi-343 omics data types and different populations/countries. Through comprehensive molecular 344 profiling, we identified that PRKCG, a brain-specific gene detectable in CSF, is a potential 345 biomarker for glioma diagnosis, prognosis and treatment prediction. Specifically, it presents 346 lower expression and higher methylation in glioma samples than normal samples. PRKCG 347 expression/methylation change from high to low is indicative of glioma progression from low-348 grade to high-grade and high RNA expression is suggestive of good survival. Importantly, 349 PRKCG in combination with MGMT is more effective to yield precise survival outcomes after 350 BLCA  BRCA  CESC  CHOL  COAD  DLBC  ESCA  GBM  HNSC  KICH  KIRC  KIRP  LAML  LGG  LIHC  LUAD  LUSC  OV  PAAD  PCPG  PRAD  READ  SARC  SKCM  STAD  TGCT  THCA  THYM  UCEC 
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